Poster Display & Cocktail
10P - In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells
Date
02 Mar 2020Session
Poster Display & CocktailPresenters
Ali Jahanian-NajafabadiCitation
Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86
Authors
A. Jahanian-Najafabadi, R. Ghavimi, V. AkbariAuthor affiliations
- Department Of Pharmaceutical Biotechnology, Isfahan University of Medical Sciences and Health Services, 8174673461 - Isfahan/IR
Resources
Resources from the same session
5P - Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents
Presenter: Paolo Tarantino
Session: Poster Display & Cocktail
Resources:
Abstract
6P - Targeting leukemic stem cells using humanized chimeric immunotoxin
Presenter: Madhumathi Jayaprakasam
Session: Poster Display & Cocktail
Resources:
Abstract
7P - Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
11P - Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
12P - IL-18 improves the anti-cancer immunity of human gamma delta T cells against prostate cancer
Presenter: Mohanad Nada
Session: Poster Display & Cocktail
Resources:
Abstract
13P - A mitigation of breast cancer-induced immune-suppressive tumor microenvironment through curbing miR-155/IL-10/TNF-α loop using a novel quercetin derivative
Presenter: Rana Youness
Session: Poster Display & Cocktail
Resources:
Abstract
14P - Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients
Presenter: Eduardo Castanon Alvarez
Session: Poster Display & Cocktail
Resources:
Abstract
20P - Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma
Presenter: Gil Awada
Session: Poster Display & Cocktail
Resources:
Abstract
21P - OX401, a new generation of PARP-interfering drug for cancer treatment
Presenter: Wael Jdey
Session: Poster Display & Cocktail
Resources:
Abstract
23P - Novel ERα degrader, 3,20(R)-dihydroxy-19-norpregnatriene, inhibits MCF-7 cell growth through p21/CDK2/CDK4 pathway
Presenter: Alexander Scherbakov
Session: Poster Display & Cocktail
Resources:
Abstract